(Finance) – The Food and Drug Administration (FDA) US approved ZAVZPRET (zavegepant), lo nasal spray Of Pfizer for the acute treatment of migraine with or without aura in adults.
The same US pharmaceutical company communicates it in a note, explaining that, in its pivotal phase 3 study, ZAVZPRET has been shown to be statistically superior to placebo in terms of freedom from pain and the most annoying symptoms after two hours from administration. The study has also demonstrated pain relief already in 15 minutes.
“The FDA approval of ZAVZPRET marks a significant breakthrough for people with migraine who need to be pain free and prefer alternative options to oral medications – said Angela Hwang, Chief Commercial Officer of Pfizer’s Global Biopharmaceuticals Business division.